Gastrodin Regulates RAS–SIRT3 and Astrocyte Phenotypes via Microglia

Study Background and Research Question

Neuroinflammation is a hallmark of many central nervous system (CNS) diseases, with reactive astrocytes and microglia serving as primary cellular mediators. The renin-angiotensin system (RAS), commonly implicated in cardiovascular homeostasis, has increasingly been identified as a key regulator of neuroinflammatory responses through its influence on glial cell phenotypes. Gastrodin, a bioactive phenolic glycoside from Gastrodia elata, is known for its anti-inflammatory and neuroprotective effects, but its impact on astrocyte–microglia signaling via RAS pathways had not been fully elucidated. The reference study sought to clarify how gastrodin regulates expression of RAS components, SIRT3, and proinflammatory mediators in reactive astrocytes, specifically examining the role of microglia-derived signals and the involvement of the angiotensin II type 1 (AT1) receptor (Zuo et al., 2024).

Key Innovation from the Reference Study

The principal innovation of this research lies in its mechanistic dissection of the microglia–astrocyte axis, revealing how gastrodin modulates RAS–SIRT3 signaling to influence astrocyte phenotype. Notably, the study provides direct evidence that AT1 receptor activity is a key node in mediating these effects—demonstrated by selective inhibition with Azilsartan (TAK-536). This links cardiovascular pharmacology with neuroinflammatory pathway modulation, expanding the utility of AT1 antagonists beyond their traditional domains.

Methods and Experimental Design Insights

The authors utilized immortalized TNC-1 astrocyte and BV-2 microglial cell lines to establish a robust in vitro model of CNS inflammation. BV-2 microglia were stimulated with lipopolysaccharide (LPS) to induce an inflammatory phenotype, then their conditioned medium (CM) was applied to TNC-1 astrocytes. Gastrodin was added to assess its effect on astrocyte responses via microglia-derived signals. Expression of RAS components (angiotensinogen [ATO], ACE, AT1, AT2), SIRT3, proinflammatory cytokines, and astrocyte phenotype markers (C3 for A1, S100A10 for A2) was evaluated using RT-PCR, immunofluorescence, and western blotting. The involvement of AT1 signaling was probed by co-treating astrocytes with Azilsartan, a potent and specific AT1 receptor inverse agonist (Azilsartan product information).

Protocol Parameters

• BV-2 microglia activation: Pre-treat with LPS (dose and duration as per study) to induce proinflammatory phenotype before collecting conditioned medium.
• Gastrodin treatment: Add gastrodin concurrently with LPS to BV-2 cells or to astrocyte cultures exposed to BV-2 CM; optimize concentration based on prior dose-response curves.
• AT1 inhibition: Apply Azilsartan (TAK-536) at concentrations validated for AT1 blockade (e.g., in the low nanomolar range, given IC₅₀ of 2.6 nM product data); dissolve in DMSO for cell culture compatibility.
• Readouts: Quantify expression of RAS components, SIRT3, C3, S100A10, inflammatory cytokines, and neurotrophic factors via RT-PCR, western blot, and immunofluorescence.
• Controls: Include untreated, LPS-only, and CM-only groups to distinguish direct and indirect effects.

Core Findings and Why They Matter

The study found that exposure of TNC-1 astrocytes to CM from LPS-activated BV-2 microglia led to pronounced upregulation of RAS components (ATO, ACE, AT1), SIRT3, proinflammatory cytokines, and the A1 astrocyte marker C3, alongside increased neurotrophic factors. Conversely, AT2 and the A2 marker S100A10 were downregulated, indicating a shift towards a neurotoxic, proinflammatory astrocyte phenotype. Gastrodin treatment reversed these effects, reducing RAS and inflammatory marker expression while enhancing SIRT3 and neurotrophic factors (IGF-1, BDNF), and restoring AT2/S100A10 levels. Importantly, selective inhibition of AT1 with Azilsartan mimicked the effects of gastrodin on astrocyte phenotype markers, demonstrating that AT1 signaling is a critical mediator of microglia-driven astrocyte activation (Zuo et al., 2024).

These results underscore the therapeutic potential of targeting AT1 in neuroinflammation, positioning Azilsartan not only as a tool for cardiovascular research, but also as a precise modulator in neuroimmune models—particularly those involving reactive astrocytes and microglia. The data support the concept of RAS–SIRT3 axis as a regulatory hub in CNS inflammation and astrocyte functional plasticity.

Comparison with Existing Internal Articles

Previous internal resources corroborate the findings of this reference study. For example, the article "Azilsartan in Renin-Angiotensin System and Neuroinflammation Models" highlights Azilsartan's utility in dissecting renin-angiotensin signaling in both cardiovascular and neuroinflammatory systems, emphasizing its reproducibility and specificity for AT1. Another resource, "Azilsartan (SKU B2210): Reliable AT1 Antagonist for Neuroinflammation Models", addresses experimental challenges and protocol optimization in glial cell assays, further validating the approach of AT1 inhibition for studying astrocyte/microglia interactions. The internal summary of the reference study, "Gastrodin Modulates RAS-SIRT3 Pathways in Astrocyte–Microglia Models", specifically notes the mechanistic link between AT1 blockade and astrocyte phenotype modulation, in line with the new findings.

Limitations and Transferability

While the study provides compelling mechanistic evidence in cell-based models, translation to in vivo systems and clinical contexts requires caution. The use of immortalized cell lines (TNC-1, BV-2) may not fully capture the heterogeneity and complexity of primary CNS glial populations. Additionally, while gastrodin and Azilsartan modulated key markers and pathways, the downstream functional consequences (e.g., neuroprotection, behavioral outcomes) were not directly assessed in this work. Thus, while the RAS–SIRT3 axis and AT1 receptor are attractive targets, further validation in animal models and patient-derived cells is necessary to determine broader applicability and potential therapeutic windows.

Research Support Resources

Researchers aiming to model the RAS–SIRT3 pathway or to investigate the modulation of reactive astrocytes and microglia can leverage high-purity, validated reagents. Azilsartan (TAK-536, SKU B2210) from APExBIO is a potent, specific AT1 receptor inverse agonist with documented IC₅₀ of 2.6 nM and DMSO solubility, suitable for cell-based RAS and inflammation studies. Its use supports reproducible blockade of AT1 signaling in models similar to those described in the reference study. Quality control documentation (HPLC, NMR, MSDS) and practical storage details are available to facilitate protocol design and reproducibility.